poisar

Stock

Novartis AG NVS

$150.88-0.55%

Overview

NVS market data

Price History

NVS price chart

Valuation & Profitability

Provider-backed
P/E (TTM)
21.95
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
$7.15
Diluted earnings per share over the trailing twelve months.
Beta
1.18
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
3.0%
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
22.5%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$95.83 – $131.50
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $227.4B · P/B 5.57 · P/S 4.94.

Company News

10 captured
Novartis India Approves Termination Of Distribution Agreement With Dr. Reddy’s Laboratories; Termination Agreement With Dr. Reddy’s Effective September 30, 2026; To Re-Buy Exclusivity And Market Access For Products After DRL Agreement TerminationBenzinga · Aug 7, 2026, 3:36 PM
Precision Medicine Collaboration and Licensing Deals 2019-2026 | Gain Access to Over 1,350 Deals and Benchmark with ConfidenceGlobenewswire Inc · Aug 7, 2026, 11:00 AM
MHRA Approves Remibrutinib For Adults With Chronic Spontaneous UrticariaBenzinga · Aug 6, 2026, 3:11 PM
BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business UpdatesGlobenewswire Inc · Aug 5, 2026, 9:15 PM
FDA Approval Nearly Doubles Eligible Patient Pool For Novartis' PluvictoBenzinga · Aug 3, 2026, 4:56 PM
Cathie Wood's $362 Million CRISPR Therapeutics Bet Isn't Just Bold -- It's Backed by a Catalyst Many Investors Are UnderratingThe Motley Fool · Jul 22, 2026, 11:00 AM
Global Cancer Biomarkers Market to Reach $37.8 Billion by 2035 as Precision Oncology Adoption Accelerates - Trends and Forecasts Till 2035Globenewswire Inc · Jul 22, 2026, 11:00 AM
Trump Sets August 1 Start for Generic Drug Tariff Clock, Warns of 200% Duties: Companies Must 'Build Plant and Equipment' in USBenzinga · Jul 22, 2026, 2:13 AM
Novartis Q2 2026 Earnings Call TranscriptBenzinga · Jul 21, 2026, 1:45 PM
Novartis Silences Generic Fears With Blowout Quarter, Packed PipelineBenzinga · Jul 21, 2026, 12:21 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock
Novartis AG (NVS) stock — price, valuation & news | Poisar